{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:15:36Z","timestamp":1794575736719,"version":"4.9.1"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Hypertension is a cause and consequence of chronic kidney disease (CKD). Resistant hypertension is common and often difficult to control in patients with CKD. This post hoc analysis evaluated the efficacy and safety of aprocitentan (with standardized background antihypertensive therapy) in patients with CKD and resistant hypertension, a group with high morbidity and mortality risk and limited treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>The PRECISION study (Parallel-Group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension) consisted of part 1: 4-week, double-blind (aprocitentan 12.5 and 25 mg versus placebo); part 2: 32-week, single-blind (aprocitentan 25 mg); and part 3: 12-week, double-blind withdrawal (aprocitentan 25 mg versus placebo). In participants with CKD, aprocitentan\u2019s effect on blood pressure (BP), urine albumin-to-creatinine ratio, and safety was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Of 730 participants in PRECISION, 147 had CKD categorized as KDIGO high risk or very high risk. At week 4, aprocitentan 12.5 mg, aprocitentan 25 mg, and placebo reduced office systolic BP by \u221213.5, \u221216.6, and \u22124.4 mm\u2009Hg, respectively; this was maintained with aprocitentan 25 mg to week 36 (\u221216.4 mm\u2009Hg). At week 4, reductions in nighttime ambulatory systolic BP were \u22129.6, \u221213.8, and \u22122.5 mm\u2009Hg, respectively. Changes in urine albumin-to-creatinine ratio were \u221247.1%, \u221259.6%, and \u22122.4%, respectively, maintained with aprocitentan 25 mg to week 36 (\u221261.6%). Aprocitentan was generally well tolerated (no change in potassium or estimated glomerular filtration rate); early peripheral edema was the most common adverse event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Aprocitentan was well tolerated; efficiently lowered BP, particularly nighttime ambulatory BP; and markedly reduced urine albumin-to-creatinine ratio in participants with CKD and resistant hypertension. Aprocitentan may confer considerable cardiovascular and kidney-protective benefits in these difficult-to-treat patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>REGISTRATION:<\/jats:title>\n                    <jats:p>\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      ; Unique identifier: NCT03541174.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/hypertensionaha.125.25563","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:00:25Z","timestamp":1765274425000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension"],"prefix":"10.1161","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-3873","authenticated-orcid":true,"given":"Patrick","family":"Rossignol","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Centre d\u2019Investigations Cliniques-Plurith\u00e9matique 1433, INSERM Unit 1116, Centre Hospitalier R\u00e9gional Universitaire (CHRU) de Nancy, and French Clinical Research Infrastructure Network Investigator Network initiative Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT), Nancy, France (P.R.)."},{"name":"Medical specialties and nephrology departments, Princess Grace Hospital, and Monaco Private Hemodialysis Centre, Monaco, and Monaco Clinical Research Infrastructure Network (M-CRIN), Monaco (P.R.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Clozel","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland (M.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland F.","family":"Dreier","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals AG, Basel, Switzerland (R.F.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2584-5598","authenticated-orcid":true,"given":"John M.","family":"Flack","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Hypertension Section, Department of Medicine, Hypertension Section, Southern Illinois University School of Medicine, Springfield, IL (J.M.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4458-7627","authenticated-orcid":true,"given":"Bruno","family":"Flamion","sequence":"additional","affiliation":[{"name":"Viatris Innovation GmbH, Allschwil, Switzerland (B.F., M.S.-S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Mann","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universit\u00e4tsklinikum Erlangen, Germany (J.M.)."},{"name":"Outpatient Clinic, KfH Kidney Centre, Munich, Germany (J.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Narkiewicz","sequence":"additional","affiliation":[{"name":"Department of Hypertension and Diabetology, Medical University of Gda\u0144sk, Poland (K.N.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Sassi-Sayadi","sequence":"additional","affiliation":[{"name":"Viatris Innovation GmbH, Allschwil, Switzerland (B.F., M.S.-S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8511-1524","authenticated-orcid":true,"given":"Ji-Guang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hypertension, The Shanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8504-0831","authenticated-orcid":true,"given":"Michael A.","family":"Weber","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Downstate College of Medicine, State University of New York, Brooklyn (M.A.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-0195","authenticated-orcid":true,"given":"Markus P.","family":"Schlaich","sequence":"additional","affiliation":[{"name":"Dobney Hypertension Centre, Royal Perth Hospital Research Foundation, Medical School, University of Western Australia, Perth, Australia (M.P.S.)."},{"name":"Department of Cardiology and Department of Nephrology, Royal Perth Hospital, WA, Australia (M.P.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003480"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09720822"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.321762"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00418-3"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpae020"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.949260"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001624"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.05.033"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14701"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.11.003"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-023-03391-z"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19996"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000170138.56903.7a"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.133900"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae178"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001356"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-024-00908-z"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02070.x"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2022-0010"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.12.014"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-023-01259-z"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206056"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.253864"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02034-7"},{"key":"e_1_3_3_27_2","unstructured":"Idorsia. TRYVIO (aprocitentan) prescribing information. 2024. Accessed November 18 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217686s000lbl.pdf"},{"key":"e_1_3_3_28_2","unstructured":"Idorsia. JERAYGO (aprocitentan) summary of product characteristics. 2024. Accessed November 18 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jeraygo-epar-product-information_en.pdf"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14517"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.124.24142"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00748-3"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.04.049"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-020-01794-8"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc11454"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae235"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2003.01924.x"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00590-0"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61212-5"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15064"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.03.003"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03850"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00733-X"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.14782"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.124.24026"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.81.suppl_1.p438"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.14504"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030131"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.06.009"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2043"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003896"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49576"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084943"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30772-X"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.01.006"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0366-6999.20122497"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1860"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2015.06.014"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-018-1385-1"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1848"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2018.07.462"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004434.pub6"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.21037\/cdt.2019.03.02"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.156976"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/nep.14130"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07340521"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.03.004"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.123.21716"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.125.25563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:21:56Z","timestamp":1782148916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.125.25563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.125.25563"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.125.25563","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}